Outcomes of Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion
Purpose: To determine the functional and anatomical outcome of intravitreal Bevacizumab in patients with
macular edema secondary to branch retinal vein occlusion.
Study Design: Quasi Experimental study.
Place and Duration of Study: Institute of Ophthalmology, Mayo hospital, Lahore, from February 2016 to December 2018.
Material and Methods: Forty eyes of 40 patients with macular edema on OCT secondary to BRVO were included in the study. All the patients suffering from other types of macular edema
caused by diabetes, epi-retinal membrane (ERM), surgery involving posterior segment, vitreoretinal traction and
history of intravitreal VEGF or steroids were excluded from the study. Intravitreal Bevacizumab was given when
macular thickness was > 300 μm or Visual acuity was < 6/12. Follow-up was at 1st, 3rd, 6th and 12th month.
Results: The mean age of the patients was 52.12 ± 5.63 years. Male to female ratio was 1.5:1. Infero-temporal
venous arcade was the most common site of BRVO (55%) followed by supero-temporal (35%) and macular
BRVO (10%). Baseline visual acuity was 6/12 or better in 17.5% of the patients at presentation. This proportion
increased to 27.5%, 40%, 52.5% and 67.5% at 1, 3, 6 and 12 months respectively. Macular thickness measured
at presentation was 540 ± 120 μm. Macular thickness gradually reduced on follow-up. At one month mean
macular thickness was 430 ± 90 μm. It was less than 300 μm after 6 months.
Conclusion: Intravitreal bevacizumab results in improved functional and anatomical outcomes in cases of
macular edema secondary to BRVO.